Core Points - A class action has been filed against Flywire Corporation on behalf of investors who acquired its securities between February 28, 2024, and February 25, 2025 [1] - Allegations include that Flywire misled investors about the sustainability of its revenue growth and downplayed the negative impact of permit and visa-related restrictions on its business [2] - On February 25, 2025, Flywire announced disappointing financial results for Q4 and FY 2024, expecting revenue declines of over 30% year-over-year in Canadian and Australian markets due to policy changes and new visa rules [3] Company Performance - Flywire's stock price fell by $6.59 per share, or 37.36%, closing at $11.05 per share on February 26, 2025, following the announcement of poor financial results and subsequent analyst downgrades [3] Legal Proceedings - Shareholders may be eligible to participate in the class action against Flywire, with options to serve as lead plaintiff or remain an absent class member [4]

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2]. - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Reporting Scrutiny - A report by Spruce Point Capital Management highlighted several red flags regarding Tempus' management and operations, including a history of executives cashing out before public shareholders incur losses [3]. - The report claims that Tempus' actual AI capabilities are overstated and that there are signs of aggressive accounting and financial reporting [3]. - Concerns were also raised about the AstraZeneca and Pathos AI deal, which merits further scrutiny [3]. - Recent financial guidance from the company reveals weaknesses in its core operations [3]. Stock Price Impact - Following the news of the allegations and the report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 on May 27, 2025, to $53.20 on May 28, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation (NASDAQ: IRBT) on behalf of investors who acquired its securities between January 29, 2024, and March 11, 2025, due to allegations of misleading statements regarding the impact of the termination of Amazon's acquisition [1][2]. Group 1: Allegations and Company Actions - iRobot and Amazon mutually agreed to terminate the acquisition in January 2024, yet iRobot claimed confidence in its ability to operate successfully as a standalone company [2][3]. - Following the acquisition termination, iRobot announced a Restructuring Plan, referred to as "iRobot Elevate," aimed at stabilizing the company and focusing on profitability and growth in mid-tier and premium segments [2][3]. - On March 12, 2025, iRobot reported disappointing financial results for Q4 and full year 2024, leading to a significant stock price drop of $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [2][3]. Group 2: Financial Stability Concerns - The lawsuit alleges that iRobot overstated the effectiveness of the Restructuring Plan and that it was unlikely to operate profitably as a standalone entity, raising doubts about its ability to continue as a going concern [3].

SAN DIEGO, July 18, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Neogen Corporation (NASDAQ: NEOG) securities between January 6, 2023 and June 3, 2025. Neogen is a food safety company that manufactures and markets products and services dedicated to food and animal safety.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Inve ...

Core Insights - Robbins LLP is investigating RxSight, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the United States [1] Company Overview - RxSight, Inc. operates in the medical technology sector, specifically in the field of ophthalmology, providing innovative solutions for cataract surgery [1] - The company is publicly traded on NASDAQ under the ticker RXST [1] Legal Context - The investigation by Robbins LLP suggests potential legal challenges for RxSight, which may impact shareholder confidence and the company's market performance [1][2] - Shareholders who have incurred losses are encouraged to seek information regarding their rights [2]

Core Viewpoint - Robbins LLP is investigating Kindercare Learning Companies, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] Company Overview - Kindercare Learning Companies, Inc. operates in the early childhood education and care services sector in the United States [1] Legal Context - Shareholders who have incurred losses in their investment in Kindercare Learning Companies, Inc. are encouraged to seek information regarding their rights [2] - Robbins LLP operates on a contingency fee basis, meaning shareholders do not pay fees or expenses unless a recovery is made [3] Firm Background - Robbins LLP has been active in shareholder rights litigation since 2002 and has recovered over $1 billion for shareholders [3]

Core Viewpoint - Robbins LLP is investigating BellRing Brands, Inc. for potential violations of securities laws and breaches of fiduciary duties by its officers and directors [1] Group 1: Company Overview - BellRing Brands, Inc. manufactures and sells nutrition products both in the U.S. and internationally [1] Group 2: Legal Investigation - The investigation aims to determine if certain officers and directors of BellRing Brands have acted against the interests of shareholders [1] - Shareholders who have incurred losses in their investments in BellRing Brands are encouraged to seek more information regarding their rights [1] Group 3: Robbins LLP Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [2] - The firm has successfully obtained over $1 billion for shareholders since its inception [2]

Core Viewpoint - Robbins LLP is investigating The J.M. Smucker Company for potential violations of securities laws and breaches of fiduciary duties by its officers and directors [1]. Group 1 - The investigation is focused on whether certain officers and directors of The J.M. Smucker Company have acted against the interests of shareholders [1]. - The J.M. Smucker Company is involved in the manufacturing and marketing of food products across the United States [1]. - Shareholders who have incurred losses in their investments are encouraged to contact Robbins LLP for information regarding their rights [1]. Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders do not pay any fees or expenses unless they recover losses [2]. - The firm has a history of helping shareholders recover over $1 billion since its inception in 2002 [2]. - Robbins LLP is recognized as a leader in shareholder rights litigation, focusing on improving corporate governance and holding executives accountable [2].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misled investors regarding the impact of the termination of its acquisition by Amazon and the effectiveness of its restructuring plan [1][2][3]. Group 1: Allegations and Company Actions - iRobot and Amazon mutually agreed to terminate the acquisition in January 2024, yet iRobot claimed confidence in its ability to operate successfully as a standalone company [2][3]. - Following the acquisition termination, iRobot announced a restructuring plan, referred to as "iRobot Elevate," aimed at stabilizing the company and focusing on profitability and market share growth [2][3]. - On March 12, 2025, iRobot reported disappointing financial results for Q4 and the full year of 2024, leading to a significant drop in stock price by $3.255 per share, or 51.58%, closing at $3.055 per share [2][3]. Group 2: Financial Stability Concerns - The lawsuit alleges that iRobot overstated the effectiveness of its restructuring plan and that it was unlikely to operate profitably as a standalone entity, raising doubts about its ability to continue as a going concern [3].